Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients - Report - MDSpire

Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients

  • By

  • Sarah E. Glynn

  • Ralph D’Agostino Jr

  • Claire M. Lanier

  • Ariel R. Choi

  • Michael Farris

  • Mohammed Abdulhaleem

  • Patrick Young

  • Yuezhu Wang

  • Margaret Smith

  • Jimmy Ruiz

  • Thomas Lycan

  • William Jeffrey Petty

  • Christina K. Cramer

  • Stephen B. Tatter

  • Adrian W. Laxton

  • Jaclyn J. White

  • Jing Su

  • Christopher T. Whitlow

  • Fei Xing

  • Michael D. Chan

  • Corbin A. Helis

  • May 25, 2026

  • 0 min

Share

Clinical Report: Genomic Risk Assessment via Liquid Biopsy in NSCLC

Overview

This study investigates the use of genomic profiling via liquid biopsy to predict neurologic mortality in patients with non-small cell lung cancer (NSCLC) who develop brain metastases. The findings suggest that genomic factors can stratify patients based on their risk of neurologic death, potentially guiding treatment decisions.

Background

The incidence of brain metastases in lung cancer patients is significant, with approximately 200,000 cases diagnosed annually in the U.S. Despite advancements in treatment, nearly 20% of patients with brain metastases still succumb to neurologic causes. Understanding the risk factors for neurologic death is crucial for improving patient outcomes and tailoring therapeutic strategies.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Genomic profiling can predict brain metastasis behavior in NSCLC patients.
  • Approximately 20% of patients with brain metastases experience neurologic death.
  • Risk factors for neurologic death include melanoma histology and larger tumor size.
  • Liquid biopsy offers a minimally invasive method for comprehensive genomic profiling.
  • Genomic factors may help differentiate patients at higher risk for neurologic death.

Clinical Implications

The ability to stratify patients based on genomic risk could lead to more personalized treatment approaches, including intensified surveillance and tailored therapeutic interventions. Clinicians should consider integrating genomic profiling into routine assessments for patients with NSCLC and brain metastases.

Conclusion

Genomic risk assessment via liquid biopsy presents a promising avenue for predicting neurologic mortality in NSCLC patients, potentially enhancing clinical decision-making and patient management.

Related Resources & Content

  1. Wake Forest School of Medicine, 2023 -- Genomic Risk Assessment via Liquid Biopsy for Predicting Neurologic Mortality in Patients with Non-Small Cell Lung Cancer
  2. the pathologist — Decentralized Liquid Biopsy Testing for Comprehensive Genomic Profiling
  3. Acta Neuropathologica — Monitoring Gliomas and Brain Metastases in Adults Through Liquid Biopsy Techniques
  4. The ASCO Post — Liquid Biopsy: Mounting Evidence Shows Clinical Utility in Tumor Monitoring
  5. the asco post — AACR 2025: Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies
  6. Decentralized Liquid Biopsy Testing for Comprehensive Genomic Profiling
  7. Monitoring Gliomas and Brain Metastases in Adults Through Liquid Biopsy Techniques
  8. Liquid Biopsy: Mounting Evidence Shows Clinical Utility in Tumor Monitoring
  9. Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
  10. Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
  11. Status: Revised

Original Source(s)

Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients

  • by Sarah E. Glynn, Ralph D’Agostino Jr, Claire M. Lanier, Ariel R. Choi, Michael Farris, Mohammed Abdulhaleem, Patrick Young, Yuezhu Wang, Margaret Smith, Jimmy Ruiz, Thomas Lycan, William Jeffrey Petty, Christina K. Cramer, Stephen B. Tatter, Adrian W. Laxton, Jaclyn J. White, Jing Su, Christopher T. Whitlow, Fei Xing, Michael D. Chan, Corbin A. Helis

  • May 25, 2026

Related Content

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min
Anti-VGCC negative and Anti-SOX1 positive Lambert-Eaton myasthenic syndrome as the initial presentation of small cell lung cancer: a case report

Tislelizumab-induced distal renal tubular acidosis presenting with life-threatening hypokalemia: a case report